Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-104162
Filing Date
2025-10-30
Accepted
2025-10-30 16:17:47
Documents
3
Period of Report
2025-10-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0263121-6k_nlspharma.htm 6-K 14341
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. AND KADIMASTEM LTD. ANNOUNCE COMPL ea026312101ex99-1_nlspharma.htm EX-99.1 13046
3 GRAPHIC ex99-1_001.jpg GRAPHIC 18345
  Complete submission text file 0001213900-25-104162.txt   53884
Mailing Address THE CIRCLE 6 8058 ZURICH Switzerland
Business Address THE CIRCLE 6 8058 ZURICH Switzerland 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 251435853
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)